comparemela.com

Latest Breaking News On - Clinical trials appendix - Page 1 : comparemela.com

AstraZeneca : BioPharmaceuticals presentation

BioPharmaceuticals Ruud Dobber, EVP and President, BioPharmaceuticals Sharon Barr, EVP, BioPharmaceuticals R&D .

Amolyt pharmaSecurities litigation reform actFinancial ambition statementsClinical trials appendixAmbition statementsTotal revenue

AstraZeneca : Rare Disease presentation - MarketScreener

Rare Disease Marc Dunoyer, CEO, Alexion and Chief Strategy Officer, AstraZeneca Gianluca Pirozzi, SVP, Head of Development and Safety, Alexion .

Amolyt pharmaSecurities litigation reform actFinancial ambition statementsClinical trials appendixAmbition statementsTotal revenue

AstraZeneca : Oncology presentation - MarketScreener

Oncology and Haematology David Fredrickson, EVP, Oncology Business Susan Galbraith, EVP, Oncology R&D Cristian.

Amolyt pharmaSecurities litigation reform actFinancial ambition statementsClinical trials appendixAmbition statementsTotal revenue

AstraZeneca: Q1 2024 results

AstraZeneca: Q1 2024 results
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomAmolyt pharmaPascal soriotDennis riedlFusion pharmaceuticals incGracell biotechnologies incDaiichi sankyo company limitedIcosavax incAlliance revenueProduct salesTotal revenueRare diseaseOperating marginTax ratePulmicort flexhalerAnnual general meeting

Q1 2024 results

Q1 2024 results
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United kingdomAmolyt pharmaPascal soriotGracell biotechnologies incAlliance revenueFusion pharmaceuticals incIcosavax incDaiichi sankyo company limitedConference callProduct salesTotal revenueRare diseaseOperating marginTax ratePulmicort flexhalerAnnual general meeting

vimarsana © 2020. All Rights Reserved.